# Consortium for Immunotherapeutics against Emerging Viral Threats

> **NIH NIH U19** · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2020 · $2,688,763

## Abstract

ABSTRACT
 We recently galvanized the Coronavirus Immunotherapeutic Consortium, CoVIC, an international effort
to conduct side-by-side analyses of leading therapeutic antibody candidates against the SARS-CoV-2 Spike
protein contributed by a range of large and small companies and academic labs on multiple continents. CoVIC
provides an opportunity for side-by-side analysis of the leading therapeutic candidates under the same assay
conditions, as well as real-time collaborative assembly of a broader, deeper dataset on the activities and
potencies of antibodies against SARS-CoV-2 than could be assembled by any single discovery effort alone. The
currently funded CoVIC studies focus largely on characteristics of the Fab region of the IgG therapeutic: binding
and mechanical neutralization, and analyze only spike from the original Wuhan reference strain of SARS-CoV-
2. The proposed supplement will provide support for critical components that are currently missing from CoVIC
but which are needed to accelerate clinical advancement of antibodies that will be safe, efficacious and offer
durable protection. We will determine Fc-mediated activities of the therapeutic antibodies, the likelihood or risk
of enhancement from clinical candidates, and which epitopes and sites of and susceptibility to mutagenic escape.
The resulting body of information will inform early and next-generation antibody therapies and will ensure that
therapeutics are known which are responsive to emerging viral variants.

## Key facts

- **NIH application ID:** 10199909
- **Project number:** 3U19AI142790-02S1
- **Recipient organization:** LA JOLLA INSTITUTE FOR IMMUNOLOGY
- **Principal Investigator:** Erica Ollmann Saphire
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $2,688,763
- **Award type:** 3
- **Project period:** 2020-07-27 → 2022-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10199909

## Citation

> US National Institutes of Health, RePORTER application 10199909, Consortium for Immunotherapeutics against Emerging Viral Threats (3U19AI142790-02S1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10199909. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*